Table 2.
Clinical and laboratory values associated with survival on univariate analysis.
| Characteristic | ORR ≥ PR (%) | P | 5-year PFS (%) | P | 5-year OS (%) | P |
|---|---|---|---|---|---|---|
| Age, years | ||||||
| <65 | 66.7 | 0.327 | 64.8 | 0.708 | 82.2 | 0.024 |
| ≥65 | 55.3 | 37.0 | 36.8 | |||
| Gender | ||||||
| Male | 64.4 | 0.197 | 46.8 | 0.530 | 65.9 | 0.130 |
| Female | 41.7 | 77.9 | 45.0 | |||
| BM lymphocyte, % | ||||||
| <50 | 63.0 | 0.461 | 61.8 | 0.478 | 40.6 | 0.610 |
| ≥50 | 52.9 | 26.2 | 52.5 | |||
| Cytogenetic abnormalities | ||||||
| Presence | 75.0 | 0.466 | 64.3 | 0.599 | 50.0 | 0.444 |
| Absence | 58.7 | 50.9 | 42.4 | |||
| Hemoglobin, g/dL | ||||||
| <11.5 | 61.3 | 0.732 | 54.3 | 0.140 | 60.2 | 0.700 |
| ≥11.5 | 55.6 | 0.0 | 87.5 | |||
| Platelet count, ×109/L | ||||||
| <100 | 69.2 | 0.479 | 0.0 | 0.049 | 61.9 | 0.124 |
| ≥100 | 58.6 | 60.6 | 63.0 | |||
| ALC, ×109/L | ||||||
| <1.0 | 20.0 | 0.069 | 33.3 | 0.611 | 40.0 | 0.224 |
| ≥1.0 | 64.6 | 54.3 | 64.6 | |||
| CRP, mg/dL | ||||||
| <5 | 58.0 | 0.817 | 46.4 | 0.937 | 65.5 | 0.096 |
| ≥5 | 61.5 | 51.3 | 48.6 | |||
| Serum β2-microglobulin, mg/L | ||||||
| <3 | 66.7 | 0.862 | 48.9 | 0.130 | 50.0 | 0.143 |
| ≥3 | 64.0 | 50.6 | 58.4 | |||
| Serum albumin, g/dL | ||||||
| <3.5 | 58.5 | 0.683 | 43.1 | 0.712 | 44.8 | 0.010 |
| ≥3.5 | 63.3 | 64.4 | 84.1 | |||
| LDH, IU/L | ||||||
| <450 | 59.7 | 0.688 | 50.1 | 0.849 | 61.8 | 0.403 |
| ≥450 | 66.7 | 65.6 | 72.9 | |||
| B symptom | ||||||
| Presence | 87.5 | 0.132 | 83.3 | 0.666 | 60.0 | 0.385 |
| Absence | 56.5 | 48.8 | 62.8 | |||
| ECOG, (%) | ||||||
| 0-1 | 67.4 | 0.057 | 68.7 | 0.012 | 72.6 | 0.004 |
| ≥2 | 43.5 | 18.1 | 26.9 | |||
| Hyperviscosity syndrome | ||||||
| Presence | 25.0 | 0.055 | 58.3 | 0.980 | 0.0 | 0.918 |
| Absence | 63.8 | 49.7 | 66.2 | |||
| Splenomegaly | ||||||
| Presence | 61.1 | 0.838 | 77.4 | 0.342 | 0.0 | 0.300 |
| Absence | 58.3 | 49.5 | 52.7 | |||
| Hepatomegaly | ||||||
| Presence | 57.1 | 0.884 | 40.0 | 0.246 | 28.6 | 0.913 |
| Absence | 60.0 | 42.5 | 45.1 | |||
| ISSWM (%) | ||||||
| Low | 57.1 | 0.567 | 66.7 | 0.912 | 50.0 | 0.380 |
| Intermediate | 58.8 | 58.7 | 58.0 | |||
| High | 75.0 | 0.0 | 58.4 | |||
| ISS (%) | ||||||
| I | 61.5 | 0.522 | 48.7 | 0.714 | 85.7 | 0.004 |
| II | 69.2 | 41.9 | 84.8 | |||
| III | 53.8 | 64.7 | 36.8 | |||
| Treatment regimen | ||||||
| Novel agent combined chemotherapy | 92.9 | 0.006 | 79.1 | 0.418 | 100.0 | 0.067 |
| Conventional chemotherapy | 52.6 | 46.3 | 53.0 |
ORR: overall response rates; PR: partial response rates; 5-year PFS: 5-year progression-free survival rates; 5-year OS: 5-year overall survival rates; BM: bone marrow; ALC: absolute lymphocyte count; CRP: C-reactive protein; LDH: lactate dehydrogenase; ECOG: Eastern Cooperative Oncology Group performance status; ISSWM: International Prognostic Scoring System for Waldenstrom's Macroglobulinemia; ISS: international staging system.